Physician profile
Muhammad Abdullah
NPI 1154614832
$4,024.64
in general payments reported to CMS, 2019-2025
24 companies · $974 in 2025
The $974 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $28.85 · 2021: $515 · 2022: $275 · 2023: $710 · 2024: $917 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,039.18 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $715.13 | 2021-2025 | Jynarque, Voyxact |
| Opko Pharmaceuticals, LLC | $269.67 | 2019-2025 | Rayaldee |
| Ardelyx, INC. | $203.72 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $196.62 | 2022-2025 | |
| Biogen, INC. | $185.59 | 2022 | |
| Abbvie INC. | $160.50 | 2021-2022 | |
| Lilly USA, LLC | $148.94 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $140.23 | 2021-2025 | Benlysta |
| Amgen INC. | $136.52 | 2023-2024 | Tavneos |
| Novo Nordisk INC | $133.82 | 2024 | Rybelsus, Ozempic |
| Emd Serono, INC. | $125.00 | 2019 | |
| Aurinia Pharma U.S., INC. | $101.74 | 2023 | Lupkynis |
| Akebia Therapeutics INC | $99.27 | 2019 | |
| Vifor Pharma, INC. | $76.18 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.87 | 2023-2024 | Jardiance |
| Horizon Therapeutics Plc | $37.50 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $27.23 | 2024-2025 | |
| Nxstage Medical, INC. | $26.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.50 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.94 | 2024 | Onpattro |
| Ge Healthcare | $22.80 | 2019 | |
| Merz North America, INC. | $16.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.